Gene expression profile of CD22 CAR T-cell products

Cytokine release syndrome (CRS) is a strong immune system response that can occur as a result of the reaction of a cellular immunotherapy with malignant cells. While the frequency and management of CRS in CAR T-cell therapy has been well documented, there is emerging interest in pre-emptive treatment to reduce CRS severity and improve overall outcomes. Accordingly, identification of genomic determinants that contribute to cytokine release may lead to the development of targeted therapies to prevent or abrogate the severity of CRS. We examined CD22 CAR T-cells using the Nanostring nCounter platform and found that the expression of the PFKFB4 gene and glycolytic pathway activity were upregulated in CAR T-cells in those who developed CRS compared to those who did not have CRS. We collected 43 CD22 CAR T-cell pre-infusion products. All of them are cryoperserved in the liquid nitrogen. Each sample has related cytokine release syndrome grade (WithoutCRS, CRSgrade1, CRSgrade2, CRSgrade3, CRSgrade4).